Hybrid adaptive immunity to SARS-CoV-2 protects against breakthrough infection after COVID-19 vaccination in ALSPAC participants

Competing Interest Statement

AF was a lead investigator on trials of COVID-19 vaccines funded by Oxford/Astra-Zeneca, Valneva and Sanofi and the UK government. He also leads a University of Bristol sponsored epidemiological study of adult respiratory disease funded by Pfizer which has evaluated COVID-19 vaccine effectiveness. During the pandemic he was a member of the Joint Committee on Vaccination and Immunisation which advised the UK government on COVID-19 vaccine policy and of the WHO Specialist Advisory Group of Experts COVID-19 vaccine working group. No other authors declare competing interests.

Funding Statement

This work was funded by UK Research and Innovation (UKRI) and the National Institute of Health Research (NIHR) through the UK COVID-19 Immunology Consortium (UK CIC). This work was supported by the Elizabeth Blackwell Institute, University of Bristol, with funding from the Wellcome Trust ISSF3 grant 204813/Z/16/Z, and the University Alumni and Friends (LW, LR, AH, AD, AF and OF). NJT is the PI of the Avon Longitudinal Study of Parents and Children (MRC & WT 217065/Z/19/Z), is supported by the University of Bristol NIHR Biomedical Research Centre (BRC-1215-2001), the MRC Integrative Epidemiology Unit (MC_UU_00011/1) and works within the CRUK Integrative Cancer Epidemiology Programme (C18281/A29019). MK is supported by the Medical Research Council (MR/W021315/1). MS is supported by the Academy of Medical Sciences (Springboard Award SB007\100173). The UK Medical Research Council and the Wellcome Trust (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors; LR, AH, LW, HEB and MS will serve as guarantors for the contents of this paper. A comprehensive list of grant funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf). This research was specifically funded by Wellcome Trust and MRC grant 102215/2/13/2. The funders had no role in the study design, data collection, data analysis nor preparation of the manuscript or decision to publish.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The ALSPAC Ethics and Law Committee at the University of Bristol gave ethical approval for this work (NHS REC 20/HRA/4854).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes